Novogene Europe announces the launch of clinical whole genome sequencing services
ISO 17025 WGS extends the range of clinical services Novogene can offer to include the most comprehensive genetic testing method for DNA-based mutations.
Novogene, a leading provider of genomic services and solutions, has announced the inclusion of clinical whole genome sequencing (WGS) under their ISO 17025 certification. This follows on from the ISO 17025 accreditation awarded to Novogene’s Cambridge lab for clinical whole exome sequencing (WES) last year.
Achieving the inclusion of our clinical WGS service under ISO 17025 provides solid assurance and confidence to Novogene’s customers in our continued ability to offer such a high standard of service in Europe. WGS covers a wide range of mutation types including single nucleotide variants and indels in both coding and noncoding regions, copy number variants, structural variants, regions of absence of heterozygosity, and repeat expansion variants. It is the most comprehensive genetic testing method for DNA-based mutations, enabling diagnoses of a complex nature.
Whole genome testing can also provide valuable insights aside from diagnosis, such as identifying the risk of developing a specific disease or whether a disease runs in a family. This can inform the decisions of medical professionals and assist them in providing effective treatments or management strategies.
“We’re delighted that our lab has received this accreditation. It allows us to make a positive difference in the diagnosis and treatment of rare diseases for our clients’ patients, helping to improve their prognosis and quality of life”, said Dong Xia, Clinical Service Director, Novogene Europe.
“This is another milestone in our journey of ISO accreditation, and now we are working towards the medical laboratory ISO15189 accreditation”, added Pingping Zhuang, Deputy General Manager, Novogene Europe. “It is proof of the high standards of our laboratory practice and the technical expertise of our lab team.”
This certification highlights Novogene’s continued commitment to its mission to advance genomics and improve life. The service is available now from Novoegne’s UK based Cambridge Sequencing Centre.
Please visit en.novogene.com or contact email@example.com for more information.
Novogene is a leading provider of genomic services and solutions with cutting edge next-generation sequencing (NGS) and bioinformatics expertise. With one of the largest sequencing capacities in the world, we utilise our deep scientific knowledge, first-class customer service and unsurpassed data quality to help clients realise their research goals in the rapidly evolving world of genomics.
With almost 2,000 employees, multiple locations around the world, 37 NGS related patents and over 670 publications in top tier journals such as Nature and Science, we have rapidly become a world-leader in NGS services.
Our Sequencing Centre in the Cambridge Science Park offers our customers an unrivalled NGS service with a quick turn-around, exceptional data quality and expert PhD level advice and support throughout your project.